Drug Profile
Iobenguane I-131 - Progenics Pharmaceuticals
Alternative Names: 131-I-metaiodobenzylguanidine; 131-I-MIGB; 131I-iobenguane - Progenics Pharmaceuticals; 131I-MIBG - Progenics Pharmaceuticals; 3-iodobenzylguanidine-I-123; Azedra; HSA I-131 MIBG; I-131 mIBG; I-131-iobenguane; Iobenguane-I123-injection; Iobenguane-I131; Iobenguane-sulfate; Iodine-123 metaiodobenzylguanidine - Progenics Pharmaceuticals; Iodine-131 iobenguane - Progenics Pharmaceuticals; Iodine-131 metaiodobenzylguanidine - Progenics Pharmaceuticals; Iodine-131-metaiodobenzylguanidine; Iodine-I-131-metaiodobenzylguanidine; m-Iodobenzylguanidine-sulfate; Meta-iodobenzylguanidine; Metaiodobenzylguanidine-I-123; Metaiodobenzylguanidine-I-131; Metaiodobenzylguanidine-sulfate; MIBG; MIP-120T; Ultratrace I-131-MIBG; Ultratrace iobenguane I 131; Ultratrace MIBG; Ultratrace-iobenguane-I-131Latest Information Update: 14 Jun 2023
Price :
$50
*
At a glance
- Originator Molecular Insight Pharmaceuticals
- Developer Progenics Pharmaceuticals
- Class Antineoplastics; Guanidines; Imaging agents; Iodobenzenes; Radiopharmaceutical diagnostics; Small molecules; Sulfates
- Mechanism of Action Cell death stimulants; Neuron inhibitors; Poly(ADP-ribose) polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Neuroendocrine tumours
- Discontinued Neuroblastoma
Most Recent Events
- 14 Jun 2023 Discontinued - Phase-II for Neuroblastoma (In children) in USA (IV) (Lantheus pipeline June 2023)
- 03 Mar 2021 Efficacy data related to biomarkers impact from a phase IIb trial in Neuroendocrine tumours presented at the 103rd Annual Meeting of the Endocrine Society (ENDO-2021)
- 16 Jun 2020 Progenics Pharmaceuticals has been acquired by Lantheus Holdings